Early combination allows for the timely introduction of non-statin agents, such as ezetimibe and PCSK9 inhibitors, which have additive LDL-C lowering effects and improve plaque stabilization, thereby further reducing cardiovascular risk after an acute coronary syndrome (ACS). The gene discussed is PCSK9; the disease is acute coronary syndrome.